Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
February 25, 2020
Revance to Participate in the Cowen 40th Annual Health Care Conference
February 24, 2020
Revance Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update
February 14, 2020
Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020
February 12, 2020
Revance Announces Pricing of $250 Million of Convertible Senior Notes Due 2027
February 10, 2020
Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027
February 6, 2020
Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines
January 10, 2020
Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA
January 9, 2020
Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference
January 9, 2020
Revance Provides Corporate Update and Anticipated Milestones for 2020
December 5, 2019
Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology
Displaying 81 - 90 of 277